By Ian Werther in News — 13 Mar 2026

Korean JW Holdings Acquires Soliders Investment, Becomes Wholly Owned Biotech Subsidiary

JW Holdings announced on the 13th that it will acquire 2 million shares of bio-focused venture investor Soliders Investment, giving JW a 100 percent stake and making Soliders Investment a wholly owned subsidiary. The deal value is 30.6 billion won, corresponding to about 2.45 percent of JW Holdings’ total assets. The acquisition expands JW’s subsidiaries to seven.

Soliders Investment is a venture capital firm specializing in biotechnology and healthcare, with early investments in prominent Korean biopharma companies such as Alteogen, Orum Therapeutics, and OLIX. It also manages a portfolio of funds, including the Smart Bio Investment Fund, the Global Healthcare Fund, and the Next Bio Star Investment Consortium, and is known for sourcing and funding early-stage biotech firms.

There is a rise of investment in clean technology supply changes projected for 2030 demonstrated in these graphs, shown through the annual manufacturing capacity for these technologies and the cumulative investment needs from the Net Zero by 2050 scenario. This graph was published as part of the International Energy Agency's Energy Technology Perspectives 2023 report. — Representative image for context; not directly related to the specific event in this article. License: CC BY 4.0. Source: Wikimedia Commons.

JW Holdings has built an investment-focused portfolio in biotech and healthcare, leveraging funds that concentrate on early-stage opportunities and growth in the sector. By absorbing Soliders Investment, JW aims to deepen its access to innovative biotech startups and expand its early-stage deal flow.

The board’s decision comes in a period when biotech investment environments have shown signs of tightening. JW says the strategic value of backing technically strong biotech firms remains high, and the acquisition is intended to broaden its financial investment activities while strengthening collaboration with biotech companies.

JW emphasizes that integrating its own foundational R&D capabilities—spanning basic research, clinical development, and regulatory affairs—with biotech partners’ innovative technologies could improve the efficiency of drug development. The company expects synergies that accelerate preclinical and clinical progress.

View of the Union Investment-Skyscraper at a sunny winter day. This image is a panorama which was stitched from 4 images. Projection is flat. — Representative image for context; not directly related to the specific event in this article. License: CC BY-SA 3.0. Source: Wikimedia Commons.

Beyond investments, JW plans to push an open-innovation R&D strategy, actively bringing in external breakthroughs and expanding collaborations with biotech firms. The company also signals that future technology transfer and potential mergers and acquisitions are on the table to secure new growth engines.

For U.S. readers, the deal illustrates Korea’s expanding role in global biotech finance and R&D collaboration. As Korean groups bolster open-innovation models and cross-border partnerships, such moves could influence international drug-development pipelines, licensing, and supply chains, and may shape how U.S. and Korean firms co-create and commercialize new therapies.

Subscribe to Journal of Korea